GUIDE-HF: CardioMEMS-Guided Meds Fall Short in Mild to Moderate Heart Failure

2021-10-26 - 2021-10

Medical therapy for heart failure (HF) guided by an implanted pulmonary artery pressure (PAP) sensor didn't improve survival or risk for HF events like hospitalization over a year in a major randomized trial that entered a broad range of patients with mild to moderate disease. But medical therapy adjustments based on PAP readings from the miniature CardioMEMS (Abbott) implant might well have surpassed conventional HF management for outcomes had the world not been turned upside down by SARS-CoV-2 and the pandemic lockdowns, assert researchers from the GUIDE-HF trial.

Brochure Form

Abstracts enquiry

Registration enquiry

Contact Enquiry

Sponsors / Advertising

Phone

WhatsApp

Useful Links

News

GUIDE-HF: CardioMEMS-Guided Meds Fall Short in Mild to Moderate Heart Failure

Newsletter

Brochure

Webinar on cardiology and Cardiovascular Therapeutics

Brochure Form

GUIDE-HF: CardioMEMS-Guided Meds Fall Short in Mild to Moderate Heart Failure